Allarity Therapeutics, Inc. (ALLR)
0.96
-0.02
(-1.63%)
USD |
NASDAQ |
Nov 06, 10:20
Allarity Therapeutics Enterprise Value : 10.83M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 10.83M |
| November 04, 2026 | 12.49M |
| November 03, 2026 | 13.28M |
| November 02, 2026 | 10.86M |
| October 30, 2026 | 9.154M |
| October 29, 2026 | 9.466M |
| October 28, 2026 | 10.42M |
| October 27, 2026 | 9.943M |
| October 26, 2026 | 9.865M |
| October 23, 2026 | 9.074M |
| October 22, 2026 | 8.775M |
| October 21, 2026 | 9.300M |
| October 20, 2026 | 9.240M |
| October 19, 2026 | 9.195M |
| October 16, 2026 | 9.545M |
| October 15, 2026 | 8.554M |
| October 14, 2026 | 9.200M |
| October 13, 2026 | 9.146M |
| October 12, 2026 | 8.990M |
| October 09, 2026 | 11.06M |
| October 08, 2026 | 10.93M |
| October 07, 2026 | 10.96M |
| October 06, 2026 | 10.98M |
| October 05, 2026 | 11.22M |
| October 02, 2026 | 11.85M |
| Date | Value |
|---|---|
| October 01, 2026 | 11.85M |
| September 30, 2026 | 12.01M |
| September 29, 2026 | 10.66M |
| September 28, 2026 | 10.71M |
| September 25, 2026 | 11.69M |
| September 24, 2026 | 12.65M |
| September 23, 2026 | 11.85M |
| September 22, 2026 | 12.97M |
| September 21, 2026 | 13.92M |
| September 18, 2026 | 14.56M |
| September 17, 2026 | 13.76M |
| September 16, 2026 | 13.68M |
| September 15, 2026 | 12.97M |
| September 14, 2026 | 13.92M |
| September 11, 2026 | 14.72M |
| September 10, 2026 | 15.19M |
| September 09, 2026 | 15.38M |
| September 08, 2026 | 15.19M |
| September 04, 2026 | 17.90M |
| September 03, 2026 | 18.06M |
| September 02, 2026 | 17.74M |
| September 01, 2026 | 17.90M |
| August 31, 2026 | 17.74M |
| August 28, 2026 | 17.74M |
| August 27, 2026 | 17.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
| Savara, Inc. | 757.02M |
| Vericel Corp. | 2.582B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.405M |
| Total Expenses (Quarterly) | 3.405M |
| EPS Diluted (Quarterly) | -0.214 |
| Earnings Yield | -81.92% |
| Normalized Earnings Yield | -81.32 |